Seeking Growth Opportunities through Understanding Market Trends, Strengthened R&D, and Global Expansion - Research Report on WellPoint, Thermo Fisher, Varian, Medicines Co., and Forest Laboratories

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, July 29, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting WellPoint Inc. (NYSE: WLP), Thermo Fisher Scientific, Inc. (NYSE: TMO), Varian Medical Systems Inc. (NYSE: VAR), Medicines Co. (NASDAQ: MDCO), and Forest Laboratories Inc. (NYSE: FRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

WellPoint Inc. Research Report

On July 24, 2013, WellPoint Inc. (WellPoint) announced its Q2 2013 financial results with net income of $800.1 million or $2.64 per share, compared with $643.6 million or $1.94 per share in Q2 2012. Adjusted net income was $2.60 per share, reflecting a 27.5% YoY increase. "We are pleased with our second quarter results and encouraged by the positive momentum we have across the organization. Our Commercial businesses continue to perform well and we have achieved improvements in our Medicaid operations, largely reflecting benefits from the Amerigroup transaction," said Joseph Swedish, Chief Executive Officer. "Looking ahead, we continue to actively prepare for the coming marketplace changes, and believe we are well-positioned for the significant growth opportunities on the horizon. We're also seeing improving trends in the Local Group and National Account ASO markets, and expect membership growth from those areas next year." The Company now anticipates full-year 2013 net income to be at least $8.00 per share, on both a GAAP and Adjusted basis. The Full Research Report on WellPoint Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/64cd_WLP]

Thermo Fisher Scientific, Inc. Research Report

On July 24, 2013, Thermo Fisher Scientific Inc. (Thermo Fisher) announced its Q2 FY 2013 financial results (period ended June 29, 2013), posting revenue growth of 4.2% YoY to $3.2 billion. Adjusted EPS grew 8.2% YoY to $1.32. The Company's operating margin expanded 30 basis points to 19.3%. Marc N. Casper, President and Chief Executive Officer of Thermo Fisher said, "It was a stand-out quarter for innovation. We unveiled three new-generation Thermo Scientific platforms to provide a broad set of customers with exceptional levels of performance, speed and ease of use. We also continued to strengthen our R&D capabilities in Asia-Pacific by establishing our new China Innovation Center in Shanghai - another example of our focus on innovating to meet our customers' needs." Thermo Fisher updated its full-year FY 2013 revenue guidance in the range of $12.8 billion to $13 billion. The Full Research Report on Thermo Fisher Scientific, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/45ed_TMO]

Varian Medical Systems Inc. Research Report

On July 24, 2013, Varian Medical Systems (Varian) announced its Q3 FY 2013 financial results (period ended June 28, 2013) posting net earnings of $1.03 per diluted share, a 7.3% YoY growth. Revenues totaled $726.2 million for the quarter, up 3% YoY. "Varian's net earnings rose versus the year-ago quarter in line with expectations while revenues rose somewhat less than expected due primarily to a significant currency headwind with the Yen as well as inventory adjustments among major X-ray tube customers in Japan," said Dow R. Wilson, Varian Medical Systems' CEO. The Company anticipates a 5% YoY growth on Company revenues for full-year FY 2013, with net earnings per diluted share in the range of $4.00 to $4.04. The Full Research Report on Varian Medical Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/bd48_VAR]

Medicines Co. Research Report

On July 24, 2013, The Medicines Company announced its Q2 2013 financial results with net revenue growth of 27.3% YoY to $172.8 million. Net income attributable to the Company totaled $18.1 million or $0.30 per share compared with net income of $13.8 million or $0.25 per share in Q2 2012. Adjusted net income increased 62.2% YoY to $29.2 million or $0.50 per share. Glenn Sblendorio, President and CFO of The Medicines Company, stated, "Our first half 2013 revenues show a continued diversification of growth sources, as our hospital portfolio and global geographies expand. Additionally, our near term anticipated growth drivers advanced significantly in the second quarter, as we reported positive Phase 3 results of the oritavancin Phase 3 SOLO II trial, filed for US approval for cangrelor, and completed clinical work toward filings for IONSYS." The Full Research Report on Medicines Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5a84_MDCO]

Forest Laboratories Inc. Research Report

On July 23, 2013, Forest Laboratories Inc. (Forest Laboratories) announced its Q1 FY 2014 financial results posting diluted EPS of $0.09 compared to $0.21 in Q1 FY 2013. According to the Company, non-GAAP EPS excluding acquisition related amortization and specified items remained flat YoY at $0.28 in Q1 FY 2014. The Company's net sales increased 6.0% YoY to $796.9 million driven by the Company's next generation products. Howard Solomon, Chairman and CEO of Forest Laboratories, said, "We are very pleased with the financial results for the quarter and particularly with the significant percentage increases in the sales of almost all of our new products and with the initial response to Linzess and Tudorza which were both launched this past December. Collectively, our next generation products had sales of $294.1 million in the quarter, representing 47.8% growth in comparison to the comparable prior year quarter." The Full Research Report on Forest Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ea24_FRX]

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.